X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs NOVARTIS - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH NOVARTIS PANACEA BIOTECH/
NOVARTIS
 
P/E (TTM) x -22.1 347.3 - View Chart
P/BV x 2.6 38.5 6.8% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 PANACEA BIOTECH   NOVARTIS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
NOVARTIS
Mar-18
PANACEA BIOTECH/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs149758 19.6%   
Low Rs82579 14.2%   
Sales per share (Unadj.) Rs84.1228.4 36.8%  
Earnings per share (Unadj.) Rs-18.331.7 -57.7%  
Cash flow per share (Unadj.) Rs-6.732.8 -20.4%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs83.7297.1 28.2%  
Shares outstanding (eoy) m61.2524.69 248.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.9 46.9%   
Avg P/E ratio x-6.321.1 -30.0%  
P/CF ratio (eoy) x-17.220.4 -84.5%  
Price / Book Value ratio x1.42.2 61.3%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m7,07416,505 42.9%   
No. of employees `0002.80.7 411.7%   
Total wages/salary Rs m1,4491,445 100.3%   
Avg. sales/employee Rs Th1,874.18,441.3 22.2%   
Avg. wages/employee Rs Th527.02,163.6 24.4%   
Avg. net profit/employee Rs Th-407.71,173.1 -34.8%   
INCOME DATA
Net Sales Rs m5,1545,639 91.4%  
Other income Rs m1001,718 5.8%   
Total revenues Rs m5,2547,357 71.4%   
Gross profit Rs m-766-63 1,226.1%  
Depreciation Rs m71125 2,810.3%   
Interest Rs m1,50355 2,717.9%   
Profit before tax Rs m-2,8811,575 -182.9%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17792 2.1%   
Profit after tax Rs m-1,121784 -143.1%  
Gross profit margin %-14.9-1.1 1,341.5%  
Effective tax rate %-0.650.3 -1.2%   
Net profit margin %-21.813.9 -156.6%  
BALANCE SHEET DATA
Current assets Rs m3,8109,522 40.0%   
Current liabilities Rs m8,3653,296 253.8%   
Net working cap to sales %-88.4110.4 -80.1%  
Current ratio x0.52.9 15.8%  
Inventory Days Days15637 425.2%  
Debtors Days Days6728 236.5%  
Net fixed assets Rs m14,48046 31,478.7%   
Share capital Rs m61123 49.7%   
"Free" reserves Rs m9037,213 12.5%   
Net worth Rs m5,1277,336 69.9%   
Long term debt Rs m5,8320-   
Total assets Rs m19,43311,105 175.0%  
Interest coverage x-0.929.5 -3.1%   
Debt to equity ratio x1.10-  
Sales to assets ratio x0.30.5 52.2%   
Return on assets %2.07.6 26.0%  
Return on equity %-21.910.7 -204.8%  
Return on capital %3.622.2 16.4%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53961 2,539.9%   
Fx outflow Rs m9423,630 25.9%   
Net fx Rs m597-3,570 -16.7%   
CASH FLOW
From Operations Rs m5991,610 37.2%  
From Investments Rs m-438687 -63.7%  
From Financial Activity Rs m-303-2,677 11.3%  
Net Cashflow Rs m-141-380 37.2%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.6 2.0 30.0%  
FIIs % 1.3 1.6 81.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 21.5 109.8%  
Shareholders   10,259 41,647 24.6%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 19, 2018 03:37 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS